1.	Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Phase: Phase III Type: Treatment Status: Active Age: 3 to 21 at diagnosis Sponsor: Other Protocol IDs: SJMB03, SJCRH-SJMB03, NCT00085202
2.	A Phase I/II Study of the Photon Radiosurgery System Phase: Phase II, Phase I Type: Treatment Status: Active Age: 2 to 32 Sponsor: Pharmaceutical / Industry Protocol IDs: CNS 0201, NCT00179907
3.	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
4.	Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 1 to 30 Sponsor: Other Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398
5.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
6.	Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
7.	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
8.	Antineoplaston Therapy in Treating Children With Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
9.	Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
10.	Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma Phase: Phase II Type: Treatment Status: Active Age: 3 to 25 Sponsor: NCI, Other Protocol IDs: 09-361, P01CA021239, NCT01063114
11.	Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 3 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000734032, COG-ACNS1123, ACNS1123, NCT01602666
12.	A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: 0 to 40 Sponsor: Other Protocol IDs: J12106, NCT01804634
13.	Phase I Study of Photodynamic Therapy With Benzoporphyrin Derivative Monoacid Ring A in Patients With Refractory Brain Tumors. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase I Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
14.	A Trial of RAD001 and Avastin in Children With Recurrent Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: RADBEV, NCT00756340
15.	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors Phase: Phase I Type: Treatment Status: Active Age: 3 to 22 Sponsor: Pharmaceutical / Industry Protocol IDs: 07-098, NCT00634231
16.	Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 months to 23 years Sponsor: Other Protocol IDs: ACH-CNS-001, NCT00876993
17.	An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma Phase: Phase I Type: Treatment Status: Active Age: Under 18 Sponsor: NINDS Protocol IDs: 090117, 09-N-0117, NCT00880061
18.	Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: 110047, 11-C-0047, NCT01259479
19.	Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 12 months to 21 years Sponsor: NCI, Other Protocol IDs: CDR0000692563, COG-ADVL1112, ADVL1112, NCT01273090
20.	Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: SorIrin1576, NCT01518413
21.	Photodynamic Therapy (PDT) for Brain Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: 163588-1, NCT01682746
22.	Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: TED12689, U1111-1128-5704, NCT01751308
23.	A Feasibility Study of SAHA Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 months to 3 years Sponsor: NCI Protocol IDs: NCI-2012-03167, PBTC-026, U01CA081457, CDR0000636148, NCT00867178
24.	Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 3 at diagnosis Sponsor: Other Protocol IDs: SJYC07, SJCRH-SJYC07, NCT00602667
25.	Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 2 to 25 Sponsor: Other Protocol IDs: 2005P001629, NCT01115777